KTRA Stock Overview
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Kintara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$5.98 |
| 52 Week Low | US$0.081 |
| Beta | 0.60 |
| 1 Month Change | 48.93% |
| 3 Month Change | 8.68% |
| 1 Year Change | -95.26% |
| 3 Year Change | -99.80% |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial
Oct 19Kintara Therapeutics GAAP EPS of -$0.52
Sep 27Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund
Aug 03Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely
Apr 12
Kintara Therapeutics shares rise on mid-stage glioblastoma trial update
May 26Kintara initiates recruitment for VAL-083's study arm in the GBM AGILE trial
Jan 13Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme
Nov 19Shareholder Returns
| KTRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 27.8% | 1.5% | 1.2% |
| 1Y | -95.3% | 1.1% | 24.7% |
Price Volatility
| KTRA volatility | |
|---|---|
| KTRA Average Weekly Movement | 27.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 2 | Robert Hoffman | www.kintara.com |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.
Kintara Therapeutics, Inc. Fundamentals Summary
| KTRA fundamental statistics | |
|---|---|
| Market cap | US$7.34m |
| Earnings (TTM) | -US$10.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs KTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KTRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.77m |
| Earnings | -US$10.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KTRA perform over the long term?
See historical performance and comparison